Trial-Results center  
Clinical trial results database in cardiology Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

DVT prophylaxis - anticoagulant - orthopedic surgery

DVT prophylaxis - antithrombotics - orthopedic surgery


Related trials

Lyon-II, 3000 - Ticlopidine vs placebo

Gardecki, 3000 - Ticlopidine vs placebo

ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)

ADVANCE 3, 2010 - apixaban vs enoxaparin

RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)

RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)

RECORD 1, 2008 - rivaroxaban vs enoxaparin

ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)

DRIVE, 2008 - SR123781A vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)

Platinum (Colwell), 2003 - ximelagatran vs Enoxaparin

PENTHIFRA–PLUS (Eriksson), 2003 - extended prophylaxis vs standard prophylaxis

EXPRESS, 2003 - ximelagatran vs Enoxaparin

METHRO III, 2002 - ximelagatran vs Enoxaparin

METHRO II, 2002 - ximelagatran vs Dalteparin



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of Acenocoumarol
  •  

    van Geloven study, 1977

    download pdf: Acenocoumarol | antithrombotics for DVT prophylaxis

    Treatments

    Studied treatment Acenocoumarol
    Control treatment UFH 4000 ·x2

    Patients

    Patients THR

    Method and design

    Randomized effectives 11 / 11 (studied vs. control)
    Blinding double blind
    Follow-up duration NA


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Symptomatic pulmonary embolism

    0 / 11
    0 / 11
    classic 1,00 [0,00;239,93]

    Deep vein thrombosis

    6 / 11
    5 / 11
    classic 1,20 [0,52;2,79]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    Deep vein thrombosis 6 / 11 (54,5%) 5 / 11 (45,5%) 1,20 [0,52;2,79]
    Symptomatic pulmonary embolism 0 / 11 (4,5%) 0 / 11 (4,5%) 1,00 [0,02;46,06]
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Deep vein thrombosis 54,55% 45,45% 9,1%

    Meta-analysis of all similar trials:

    anticoagulant in DVT prophylaxis for orthopedic surgery

    antithrombotics in DVT prophylaxis for orthopedic surgery



    Reference(s)

    Trials register # NA
    • van Geloven F, Wittebol P, Sixma JJ. Comparison of postoperative coumarin, dextran 40 and subcutaneous heparin in the prevention of postoperative deep vein thrombosis.. Acta Med Scand 1977;202:367-72
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend